Fighting hand in hand – Mirocals update
Sadly, and frustratingly, we still await the Mirocals trial results, 13 months after the top line data was released and some 18 months after the trial ended.
We hear you all saying, “That’s the same old update!”
Yes, and you would be right.
However, until we hear that the trial has failed or the data is finally released, we will continue to apply polite but firm pressure on the Mirocals Consortium, a body entirely funded by taxpayers and charity donations.
We will continue to update our primary Mirocals page. If you have not read the whole page we encourage you to do so. While the latest updates are highlighted in yellow at the very top, reading the complete page, which is presented as 6 questions and answers, will give you the up to date full picture as we understand it. We will always reflect updates in both the highlighted section and, in full, within the 6 question answers.
Without the results, and in effect a confirmation of whether the treatment candidate, Proleukin, is effective, we can only continue preparation (as outlined on the Mirocals update page) for the, hopefully, positive outcome.
It is especially important to note that with reference to the most immediate NHS Specials pathway, full regulatory approval is NOT required although doctors and neurologists will need to be convinced of the scientific evidence supporting use of Proleukin in a lower dose, as per the trial.
Once they have seen the evidence, we are hopeful doctors will prescribe the drug, because, while it is currently unlicensed for MND, it is already licensed for other conditions and readily available via the NHS. However, there will still be barriers to overcome e.g. getting funding for the drug approved by a local health authority.
Patients United to End MND continues to prepare for this eventuality and to urge our charities and scientists to show they are fighting hand in hand with us to enable access for patients as quickly as possible in the event of positive results emerging.
We are United2EndMND - Changing the conversation 